FLUOROURACILE PFIZER 50 mg/mL

DRUG4 trials

Sponsors

Centre Leon Berard, IRCCS Istituto Nazionale Tumori Fondazione Pascale, Hospices Civils De Lyon, Association Gercor

Conditions

MSI-H/dMMR gastric cancerPatient with locally advanced/metastaticPatients with ras-mutated metastatIc colorectal cancerThe patients enrolled in IMMUNORARE will be adult patients with 5 rare cancers: -Cohort 1: Peritoneal mesotheliomas (PM) -Cohort 2: Gestational trophoblastic tumors (GTT) -Cohort 3: B3 thymomas and thymic carcinomas (TET) -Cohort 4: Anaplastic thyroid carcinomas (ATC) -Cohort 5: GEP-NET & carcinoid tumors (GEP-NET/TCT/UP-NET) Patients will have advanced/metastatic cancers found to be progressive/resistant after at least one previous line of standard systemic treatment.locally advanced or metastatic Pancreatic ductal adenocarcinoma

Phase 2

A randomized non-comparative phase II study of Maintenance therapy with OSE2101 plus FOLFIRI, or FOLFIRI after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic Pancreatic ductal adenocarcinoma.

Not yet recruitingCTIS2024-518139-12-00

Association Gercorlocally advanced or metastatic Pancreatic ductal adenocarcinoma

Target: 106Updated: 2024-11-14

REVOLUTION - Randomized phasE 2 study of Valproic acid in combination with bevacizumab and Oxaliplatin/fLUoropyrimidine regimens in patients with ras-mutated metastaTIc cOlorectal caNcer

Active, not recruitingCTIS2024-516844-25-01

IRCCS Istituto Nazionale Tumori Fondazione PascalePatients with ras-mutated metastatIc colorectal cancer

Start: 2019-01-03Target: 200Updated: 2025-07-22

IMMUNORARE5 : A national platform of 5 academic phase II trials coordinated by Lyon university hospital to assess the safety and the efficacy of the IMMUNOtherapy with Domvanalimab + Zimberelimab combination in patients with advanced RARE cancers

SuspendedCTIS2024-517254-99-00

Hospices Civils De LyonThe patients enrolled in IMMUNORARE will be adult patients with 5 rare cancers: -Cohort 1: Peritoneal mesotheliomas (PM) -Cohort 2: Gestational trophoblastic tumors (GTT) -Cohort 3: B3 thymomas and thymic carcinomas (TET) -Cohort 4: Anaplastic thyroid carcinomas (ATC) -Cohort 5: GEP-NET & carcinoid tumors (GEP-NET/TCT/UP-NET) Patients will have advanced/metastatic cancers found to be progressive/resistant after at least one previous line of standard systemic treatment.

Start: 2025-09-16Target: 186Updated: 2026-01-07

Phase 3

CIME - Combination of Immune checkpoint in locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas : A multicenter, randomised, comparative, open-label Phase III aiming to compare the survival of patients with locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas treated by a combination of Immune checkpoint inhibitors (botensilimab + balstilimab) versus the standard of care (FOLFOX/XELOX + nivolumab)

Not yet recruitingCTIS2023-506291-28-00

Centre Leon BerardMSI-H/dMMR gastric cancer, Patient with locally advanced/metastatic

Target: 132Updated: 2026-01-15